Results 261 to 270 of about 199,492 (387)

Lipid metabolism reprograming by SREBP1‐PCSK9 targeting sensitizes pancreatic cancer to immunochemotherapy

open access: yesCancer Communications, EarlyView.
Abstract Background Pancreatic cancer's aberrant lipid metabolism fuels cell growth, invasion, and metastasis, yet its impact on immune surveillance and immunotherapy is unclear. This study investigated how sterol regulatory element‐binding transcription factor 1 (SREBP1)‐driven lipid metabolism affects the tumor microenvironment (TME) in pancreatic ...
Mengyi Lao   +12 more
wiley   +1 more source

Ubiquitination in cancer: mechanisms and therapeutic opportunities

open access: yesCancer Communications, EarlyView.
Abstract Ubiquitination, a key post‐translational modification, plays an essential role in tumor biology by regulating fundamental cellular processes, such as metabolism and cell death. Additionally, it interacts with other post‐translational modifications, which are closely linked to tumorigenesis, tumor progression, the tumor microenvironment, and ...
Susi Zhu   +7 more
wiley   +1 more source

Inducible protein degradation reveals inflammation-dependent function of the T<sub>reg</sub> cell lineage-defining transcription factor Foxp3. [PDF]

open access: yesSci Immunol
Jäger C   +10 more
europepmc   +1 more source

Expression and functional characterization of FOXP3+CD4+ regulatory T cells in ulcerative colitis [PDF]

open access: bronze, 2006
Qi Yu   +5 more
openalex   +1 more source

Targeting Ubiquitin‐Specific Protease 7 with Novel 5‐Amino‐Pyrazole Inhibitors: Design, Synthesis, and Biological Evaluation

open access: yesChemMedChem, EarlyView.
Ubiquitin‐specific protease 7 (USP‐7) is a novel target for anticancer therapy. To further extend the structure–activity relationships of the previously USP‐7 inhibitor STIRUR‐41, a library of 5‐aminopyrazoles is reported. 1d shows a potency comparable to lead compound STIRUR‐41 and promising in silico and in vitro pharmacokinetic properties ...
Matteo Lusardi   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy